Related Experiment Video
Updated: May 5, 2026
09:54
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
1.8K
A Single-center Experience With >200 Lung Transplant Recipients With COVID-19 Infection
Hiromu Kehara1, Ashley Johnson-Whiting1, Roh Yanagida1
1Division of Cardiovascular Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Transplantation Direct
|September 2, 2024
Summary
COVID-19 survival in lung transplant recipients is improving, but in-hospital deaths remain high. Vaccination helps prevent hospital admission, though its effect on mortality needs more study.
Area of Science:
- Transplant Surgery
- Infectious Diseases
- Pulmonology
Background:
- Limited data exist on COVID-19's impact on lung transplant recipients.
- COVID-19 is no longer a declared global health emergency.
Purpose of the Study:
- To investigate clinical outcomes of lung transplant recipients diagnosed with COVID-19.
- To analyze outcomes based on COVID-19 diagnosis waves and vaccination status.
Main Methods:
- Retrospective analysis of lung transplant recipients diagnosed with COVID-19 (March 2020-August 2022).
- Outcomes stratified by COVID-19 diagnosis waves.
- Comparison of outcomes based on vaccination status.
Main Results:
- Overall survival was 67.1% at 1 year and 59.0% at 2 years post-COVID-19 diagnosis.
- In-hospital mortality remained high across all waves (28%-38%).
- Vaccination was protective against hospital admission; age ≥70 and partial vaccination were risk factors for in-hospital mortality.
Conclusions:
- Survival post-COVID-19 is improving in lung transplant recipients, but in-hospital mortality is high.
- Vaccination may prevent hospital admission but its impact on mortality requires further investigation.
- Identifying high-risk lung transplant recipients for COVID-19 mortality is crucial.
